Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
4
×
biotech
life sciences
4
×
national
national blog main
national top stories
4
×
new york top stories
novartis
san francisco top stories
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
gene therapy
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
aducanumab
alzheimer's disease
cancer
clinical trials
crispr
digital health
drug prices
europe top stories
gilead sciences
What
new
4
×
bio
roundup
drug
fda
ipo
remains
activity
allogene
approval
approvals
approved
atrophy
biogen
biogen’s
biopharmaceutical
cancer
clamped
companies
convo
covid
crispr
daily
delays
developing
diversity
earlier
economic
evrysdi
failures
fast
friday
green
home
hot
immunotherapy
including
intended
investors
isn’t
Language
unset
Current search:
biogen
×
new
×
" san francisco top stories "
×
" life sciences "
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More